Caribou Biosciences Stock Income Statements

Caribou Biosciences Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Caribou Biosciences Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30

licensing and collaboration revenue	3,558,000	23,662,000	3,755,000	3,502,000	3,692,000	3,303,000	4,192,000	2,664,000	2,559,000	3,977,000	1,476,000
operating expenses:
research and development	31,279,000	28,584,000	26,503,000	25,709,000	25,736,000	19,991,000	22,579,000	13,924,000	15,111,000	15,833,000	12,327,000
general and administrative	9,721,000	9,711,000	10,120,000	8,909,000	8,534,000	9,849,000	10,044,000	9,593,000	7,853,000	6,760,000	5,113,000
total operating expenses	41,000,000	38,295,000	36,623,000	34,618,000	34,270,000	29,840,000	32,623,000	23,517,000	22,964,000	22,593,000	17,440,000
income from operations	-37,442,000	-14,633,000	-32,868,000	-31,116,000	-30,578,000	-26,537,000	-28,431,000	-20,853,000	-20,405,000	-18,616,000	-15,964,000
yoy	22.45%	-44.86%	15.61%	49.22%	49.86%	42.55%	78.09%
qoq	155.87%	-55.48%	5.63%	1.76%	15.23%	-6.66%	36.34%	2.20%	9.61%	16.61%
operating margin %
other income:
change in fair value of equity securities	-9,000	-4,000	22,000	-15,000	-60,000	31,000	-16,000	-88,000
change in fair value of the mskcc success payments liability	-1,683,000	-139,000	279,000	255,000	1,388,000	-1,607,000	1,052,000	1,596,000	2,158,000	-2,403,000
other income	4,822,000	4,774,000	3,048,000	2,832,000	2,331,000	1,466,000	698,000		13,000	23,000	25,000
total other income	3,130,000	4,631,000	3,349,000	3,072,000	3,659,000	-110,000	1,734,000	1,765,000	2,247,000	-2,358,000	1,653,000
net income	-34,505,000	-10,002,000	-29,519,000	-28,044,000	-26,989,000	-26,647,000	-26,697,000	-19,088,000
yoy	27.85%	-62.46%	10.57%	46.92%
qoq	244.98%	-66.12%	5.26%	3.91%	1.28%	-0.19%	39.86%
net income margin %
other comprehensive income:
net unrealized gain on available-for-sale marketable securities, net of tax	134,250	155,000	-406,000	788,000
net comprehensive loss	-33,494,000	-9,847,000	-29,925,000	-27,256,000	-26,472,000	-27,101,000	-27,189,000	-20,042,000
net income per share	-0.4	-0.12	-0.48	-0.46	-0.45	-0.44	-0.44	-0.32	0.09	-0.46	-1.39
weighted-average common shares outstanding, basic and diluted	73,807,597	83,783,992	61,417,934	61,186,514	60,801,133	60,886,921	60,757,689	60,546,170	31,663,243	45,889,646	10,261,770
gain on extinguishment of ppp loan											1,584,000
other comprehensive loss:
net unrealized loss on available-for-sale marketable securities, net of tax					-475,000	-454,000	-492,000	-954,000
other income - net								257,000
interest income									76,000	22,000	46,000
interest expense											-2,000
net income before benefit from income taxes									-18,158,000	-20,974,000	-14,311,000
benefit from income taxes
net income and comprehensive loss									-12,111,000	-20,974,000	-14,311,000

We provide you with 20 years income statements for Caribou Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Caribou Biosciences stock. Explore the full financial landscape of Caribou Biosciences stock with our expertly curated income statements.

The information provided in this report about Caribou Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.